Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression

Conclusion: 68Ga-BMS-986192 enables easy radiosynthesis and shows excellent in vitro and in vivo PD-L1–targeting characteristics. The high tumor uptake combined with low background accumulation at early imaging time points demonstrates the feasibility of 68Ga-BMS-986192 for imaging of PD-L1 expression in tumors and is encouraging for further clinical applications of PD-L1 ligands.

Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Robu, S., Richter, A., Gosmann, D., Seidl, C., Leung, D., Hayes, W., Cohen, D., Morin, P., Donnelly, D. J., Lipovšek, D., Bonacorsi, S. J., Smith, A., Steiger, K., Aulehner, C., Krackhardt, A. M., Weber, W. A. Tags: Basic Source Type: research